"The study’s primary endpoint is pathologic complete response. Secondary endpoints include safety and biomarker evaluation."
They're going in for the kill!
Ann: Clinical Trial Supply Agreement with Merck KGaA and Pfizer, page-28
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $304.9M | |||
| Open | High | Low | Value | Volume |
| 4.1¢ | 4.2¢ | 4.1¢ | $456.6K | 11.10M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 3248478 | 4.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 2261698 | 8 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |